Target identification will commence on 17 September 2024, following the timeline provided in the campaign guidelines
India's bio economy has experienced remarkable growth, skyrocketing from US $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational therapies
The conference aims to bring various stakeholders and experts in the field of healthcare and digital solutions for ensuring ‘universal access to affordable and quality healthcare’
Transform healthcare by integrating expertise from AI, clinical sciences, and basic sciences to harness India’s extensive data sets for improving the access to healthcare
Phase 3 clinical trial designed to evaluate the safety and efficacy of tivozanib in combination with nivolumab
Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases
The emergence of new infections in India is a growing concern
Subscribe To Our Newsletter & Stay Updated
